Osteoprotegerin and its cognate ligand: a new paradigm of osteoclastogenesis.
作者信息
Hofbauer L C, Heufelder A E
机构信息
Endocrine Research Unit, Mayo Clinic, Rochester, Minnesota 55905, USA.
出版信息
Eur J Endocrinol. 1998 Aug;139(2):152-4. doi: 10.1530/eje.0.1390152.
PMID:9724069
Abstract
摘要
相似文献
1
Osteoprotegerin and its cognate ligand: a new paradigm of osteoclastogenesis.骨保护素及其同源配体：破骨细胞生成的新范式。
Eur J Endocrinol. 1998 Aug;139(2):152-4. doi: 10.1530/eje.0.1390152.
2
Pathophysiology of RANK ligand (RANKL) and osteoprotegerin (OPG).核因子κB受体活化因子配体（RANKL）与骨保护素（OPG）的病理生理学
Ann Endocrinol (Paris). 2006 Apr;67(2):139-41. doi: 10.1016/s0003-4266(06)72569-0.
3
[Osteoprotegrin and RANKL/RANK system: is it the future of bone metabolism?].[骨保护素与RANKL/RANK系统：它会是骨代谢的未来吗？]
An Med Interna. 2002 Aug;19(8):385-88.
4
Osteoprotegerin and its ligand: A new paradigm for regulation of osteoclastogenesis and bone resorption.骨保护素及其配体：破骨细胞生成与骨吸收调控的新范式。
Medscape Womens Health. 2000 Mar;5(2):5.
5
The osteoprotegerin/osteoprotegerin ligand family: role in inflammation and bone loss.骨保护素/骨保护素配体家族：在炎症和骨质流失中的作用
J Rheumatol. 2004 May;31(5):844-6.
6
Osteoprotegerin ligand and osteoprotegerin: novel implications for osteoclast biology and bone metabolism.骨保护素配体与骨保护素：对破骨细胞生物学及骨代谢的新启示
Eur J Endocrinol. 1999 Sep;141(3):195-210. doi: 10.1530/eje.0.1410195.
7
Osteoprotegerin, RANK, RANKL.骨保护素、核因子κB受体活化因子、核因子κB受体活化因子配体
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2001 Dec;145(2):61-4. doi: 10.5507/bp.2001.013.
8
The mechanisms of estrogen regulation of bone resorption.雌激素调节骨吸收的机制。
J Clin Invest. 2000 Nov;106(10):1203-4. doi: 10.1172/JCI11468.
9
[Molecular mechanism of bone metabolism].[骨代谢的分子机制]
Nihon Naika Gakkai Zasshi. 2000 Oct 10;89(10):2046-53.
10
Endogenous production of TGF-beta is essential for osteoclastogenesis induced by a combination of receptor activator of NF-kappa B ligand and macrophage-colony-stimulating factor.转化生长因子-β的内源性产生对于由核因子κB受体激活剂配体和巨噬细胞集落刺激因子联合诱导的破骨细胞生成至关重要。
J Immunol. 2000 Oct 15;165(8):4254-63. doi: 10.4049/jimmunol.165.8.4254.
引用本文的文献
1
p57Kip2 is an essential regulator of vitamin D receptor-dependent mechanisms.p57Kip2 是维生素 D 受体依赖性机制的必需调节因子。
PLoS One. 2023 Feb 15;18(2):e0276838. doi: 10.1371/journal.pone.0276838. eCollection 2023.
2
Osteosarcoma Pathogenesis Leads the Way to New Target Treatments.成骨肉瘤发病机制为新靶点治疗开辟道路。
Int J Mol Sci. 2021 Jan 15;22(2):813. doi: 10.3390/ijms22020813.
3
Efficacy of 8 Gy Single Fraction Palliative Radiation Therapy in Painful Bone Metastases: A Single Institution Experience.8 Gy单次分割姑息性放射治疗对疼痛性骨转移瘤的疗效：单机构经验
Cureus. 2018 Jan 8;10(1):e2036. doi: 10.7759/cureus.2036.
4
Molecular Pathogenesis and Diagnostic Imaging of Metastatic Jaw Tumors.转移性颌骨肿瘤的分子发病机制与诊断影像学
J Pharm Bioallied Sci. 2017 Nov;9(Suppl 1):S15-S22. doi: 10.4103/jpbs.JPBS_138_17.
5
NF-Kβ Activation in U266 Cells on Mesenchymal Stem Cells.间充质干细胞上U266细胞中的核因子κB激活
Adv Pharm Bull. 2016 Sep;6(3):415-422. doi: 10.15171/apb.2016.054. Epub 2016 Sep 25.
6
Myeloma bone disease: Pathophysiology and management.骨髓瘤骨病：病理生理学与管理
J Bone Oncol. 2013 Apr 18;2(2):59-69. doi: 10.1016/j.jbo.2013.04.001. eCollection 2013 Jun.
7
Combined effect of bisphosphonate and recombinant human bone morphogenetic protein 2 on bone healing of rat calvarial defects.双膦酸盐与重组人骨形态发生蛋白2对大鼠颅骨缺损骨愈合的联合作用
Maxillofac Plast Reconstr Surg. 2015 Jul 2;37(1):16. doi: 10.1186/s40902-015-0015-3. eCollection 2015 Dec.
8
New and emerging therapies for bone metastases in genitourinary cancers.泌尿系统癌症骨转移的新型和新兴疗法。
Eur Urol. 2013 Feb;63(2):309-20. doi: 10.1016/j.eururo.2012.10.007. Epub 2012 Nov 23.
9
Expression of osteoprotegerin and receptor activator of nuclear factor κB ligand in root resorption induced by heavy force in rats.大鼠重力诱导牙根吸收中骨保护素及核因子κB受体活化因子配体的表达
J Orofac Orthop. 2011 Nov;72(6):457-68. doi: 10.1007/s00056-011-0050-3. Epub 2011 Nov 30.
10
The molecular pathogenesis of osteosarcoma: a review.骨肉瘤的分子发病机制：综述
Sarcoma. 2011;2011:959248. doi: 10.1155/2011/959248. Epub 2011 Apr 13.
Zotero 插件